WASHINGTON (Xinhua) – The U.S. Food and Drug Administration (FDA) approved Kalydeco for the treatment of a rare form of cystic fibrosis in patients aged six years and older who have the specific G551D mutation in the CFTR gene.
Read more…
The U.S. Food and Drug Administration recently approved Byetta, a Type 2 diabetes medication created by Amylin Pharmaceuticals, Inc., for use in concert with insulin glargine—the most popular type of insulin, used around the world by diabetics.
Read more…
LONDON (AP) — Danish researchers can offer some reassurance if you’re concerned about your cellphone: Don’t worry. Your device is probably safe.
The biggest study ever to examine the possible connection between cellphones and cancer found no evidence of any link, suggesting that billions of people who are rarely more than a few inches from their phones have no special health concerns.
Read more…
TRENTON, N.J. (AP) — A severe shortage of drugs for chemotherapy, infections and other serious ailments is endangering patients and forcing hospitals to buy life-saving medications from secondary suppliers at huge markups because they can’t get them any other way.
Read more…
Keppra has improved on its dosage, unveiling the Once-daily Keppra XR extended-release tablets which are now available in a new dosage strength, 750 mg. This enables doctors to simplify patients’ treatment plans by decreasing the number of tablets they take each day.
According to studies published in Epilepsy & Behavior and Neurology, patients are more likely to adhere to their medication regimen when it is taken once daily, and therefore may be more likely to reach the goal of epilepsy therapy–seizure freedom with minimal side effects.
Keppra XR was approved by the U.S. Food and Drug Administration (FDA) based on data from an international clinical study of 158 epilepsy patients with partial-onset seizures who added 1,000 mg of Keppra XR or placebo to their other epilepsy medications once daily. The study consisted of an 8-week baseline period followed by a 12-week treatment period.
Keppra XR is also available in 500 mg tablet strength. Data presented at last year’s American Epilepsy Society meeting demonstrated that taking two 750 mg levetiracetam extended-release tablets is the same as taking three 500 mg extended-release tablets.
Treatment with Keppra XR should be initiated with a dose of 1,000 mg once daily. The daily dosage may be adjusted in increments of 1,000 mg every two weeks, to a maximum recommended dose of 3,000 mg per day.
(Source) Press
